Anda belum login :: 03 Jun 2025 03:11 WIB
Detail
ArtikelNovel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review  
Oleh: Lewis, Erin I. ; Chason, Rebecca J. ; DeCherney, Alan H. ; Armstrong, Alicia ; Elkas, John
Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 99 no. 07 (Jun. 2013), page 2017-2024.
Topik: Benign metastasizing leiomyoma; uterine leiomyoma; hormone therapy; intravenous leiomyomatosis; leiomyomatosis peritonealis disseminata
Ketersediaan
  • Perpustakaan FK
    • Nomor Panggil: F02.K.2013.04
    • Non-tandon: 1 (dapat dipinjam: 0)
    • Tandon: tidak ada
    Lihat Detail Induk
Isi artikelObjective To evaluate novel hormonal therapies in patients with unresectable benign metastasizing leiomyoma (BML) disease. Design Case series. Setting National Institutes of Health (NIH). Patient(s) Five subjects with the diagnosis of BML based on imaging and/or histopathologic diagnosis. Intervention(s) Four patients were treated with single or combination therapy of leuprolide acetate and/or an aromatase inhibitor. One patient was treated with an antiprogestin (CDB-2914). Main Outcome Measure(s) Response to therapy was measured by tumor burden on cross-sectional imaging employing RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 guidelines. Result(s) Four patients treated with single or combination therapy of leuprolide acetate and/or an aromatase inhibitor demonstrated stable disease with reduction in tumor burden. The fifth patient treated with antiprogestin (CDB-2914) had degeneration of her tumor, progression of its size, and an improvement in symptoms. Conclusion(s) Hormone treatment with GnRH agonist and/or aromatase inhibition may be a therapeutic option to reduce tumor burden in unresectable BML disease or for those patients who wish to avoid surgical intervention. RECIST 1.1 guidelines, while traditionally used to evaluate tumor response to cancer therapeutics, may be useful in evaluating BML tumor burden response to hormone therapy.
Opini AndaKlik untuk menuliskan opini Anda tentang koleksi ini!

Kembali
design
 
Process time: 0.015625 second(s)